Registry to Evaluate Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting

EXCELLENT (Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing) Registry

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00960648

Enrollment

3056

Registered

2009-08-18

Start date

2008-04-01

Completion date

2014-01-01

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Everolimus, Sirolimus, Drug eluting stent

Brief summary

The objective of this study is to evaluate the safety and long-term effectiveness of coronary stenting with the everolimus-eluting stent (EES) and to determine clinical device and procedural success during commercial use of EES in the real world. The investigators will compare EES (Xience/Promus, prospective arm) with sirolimus-eluting stent (SES, Cypher, retrospective arm).

Interventions

DEVICEXience/Promus

Active prospective registration of patients receiving everolimus-eluting stent

DEVICECypher

Retrospective historical controls that received sirolimus-eluting stent

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* The patient agrees to participate in this study by signing the informed consent form. * Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form.

Exclusion criteria

* There are no

Design outcomes

Primary

Measure	Time frame
Major Adverse Cardiac Events (composite of cardiac death, non-fatal MI, target lesion revascularization)	12 months

Secondary

Measure	Time frame
In-stent & In-segment Late Loss	9 months
Stent Thrombosis	1 year
Target Vessel Failure (composite of cardiac death, MI, and TVR)	12 months
Any death, cardiac death, MI, TLR, TVR	1 year
Composite rate of cardiac death and any MI	1 year
Composite rate of all death and any MI	1 year
Composite rate of all death, any MI (Q-wave and non Q-wave) and any repeat revascularization	1 year
Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy	1 year
Clinical device and procedural success	During the health care facility stay

Countries

South Korea

Contacts

STUDY_CHAIRHyo-Soo Kim, MD,PhD

Seoul National University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 28, 2026